Cadila Healthcare announced that the USFDA inspected its Moraiya facility from February 5th to February 9th, 2018. At the end of the inspection, no observation (483) is issued.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 21000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

Shares of the company gained Rs 13.35, or 3.25%, to trade at Rs 424.40. The total volume of shares traded was 68,658 at the BSE (12.38 p.m., Monday).